Psychometric analyses of QOL-B V. 3.0 used data from two double-blind , multicentre , randomised , placebo-controlled , phase III trials of aztreonam for inhalation solution ( AZLI ) in 542 patients with non-CF bronchiectasis and Gram-negative endobronchial infection .